Clinical analysis of 28 cases of pediatric myelodysplastic syndrome

XI Wei-Bo; WANG Dao; LIU Yu-Feng

doi:10.7499/j.issn.1008-8830.2013.07.003

PDF(1042 KB)

Chinese Journal of Contemporary Pediatrics ›› 2013, Vol. 15 ›› Issue (7) : 514-518. DOI: 10.7499/j.issn.1008-8830.2013.07.003

CLINICAL RESEARCH

Clinical analysis of 28 cases of pediatric myelodysplastic syndrome

XI Wei-Bo, WANG Dao, LIU Yu-Feng

Author information +

History +

Abstract

OBJECTIVE: To explore the clinical features, diagnosis and treatment of pediatric myelodysplastic syndrome (MDS). METHODS: Twenty-eight children with MDS between January 2006 and March 2012 were enrolled in the study. Clinical symptoms, signs, laboratory examinations, treatment and outcomes were retrospectively studied. RESULTS: Anemia (96%), bleeding (68%), fever (68%) and hepatosplenomegaly (61%) were main clinical manifestaions in the 28 patients. Three cases (11%) converted into acute monocytic leukemia (M5), erythroleukemia (M6) or acute megakaryocytic leukemia (M7) one to two months later. Bone marrow proliferation mainly demonstrated as active or obviously active. One or two lineages of hematopoietic dysplasia were mostly observed in all 28 cases and obvious iron metabolism disorders were found in these patients. Cytogenetic abnormalities were detected in 45% of the 28 cases, most of which were numeral chromosome abnormalities. T cell, B cell and NK cell numbers decreased, Th cell numbers decreased, Ts cell numbers increased and Th /Ts inversed. Eight cases gave up treatment when confirmed. Of the 8 cases receiving symptomatic and supportive treatment alone, one was lost, one showed disease stability, and the remaining 6 cases showed disease progression. One patient who underwent induced differentiation and one who received hematopoietic therapy showed disease progression. Ten patients underwent chemotherapy. Two cases had no bone marrow remission after single agent chemotherapy. Of the 8 cases who underwent multi-drug combination chemotherapy, 4 cases achieved partial or complete remission of bone marrow. CONCLUSIONS: Pediatric MDS is characterized by a lack of typical clinical manifestations, and a high rate of conversion to leukemia. Bone marrow proliferation is mainly active in children with MDS. One or two lineages of hematopoietic dysplasia is common. Among the cytogenetic abnormalities, numeral chromosome abnormalities are common. Obvious iron metabolism disorders and abnormal cellular immunity are found in children with MDS. Multi-drug combination chemotherapy appears to slow the course of the disease.

Key words

Myelodysplastic syndrome / Clinical feature / Treatment / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

XI Wei-Bo, WANG Dao, LIU Yu-Feng. Clinical analysis of 28 cases of pediatric myelodysplastic syndrome[J]. Chinese Journal of Contemporary Pediatrics. 2013, 15(7): 514-518 https://doi.org/10.7499/j.issn.1008-8830.2013.07.003

References

［1］Passmore SJ, Chessells JM, Kempski H, Hann IM, Brownbill PA, Stiller CA. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a populationbased study of incidence and survival［J］. Br J Haematol, 2003, 121(5) : 758-767.

［2］Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases［J］. Leukemia, 2003, 17(2) : 277-282.

［3］Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization(WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes［J］. Blood, 2009, 114(5): 937-951.

［4］中华医学会血液学分会．骨髓增生异常综合征诊断与治疗专家共识［J］. 中华血液学杂志，2012, 33(4): 347-352.

［5］姚玉前，戴碧涛．骨髓增生异常综合征流行病学的研究进展［J］. 儿科药学杂志, 2012, (18): 52-55.

［6］Gologan R. Epidemiological data on myelodysplastic syndrome patients under 50 years in a single center of Romania［J］．Leuk Res, 2010, 34(11) : 1442-1446.

［7］庞菊萍, 王赛娟, 孙熠, 文金全, 王华, 刘安生. 小儿骨髓增生异常综合征34例分析［J］. 中国小儿血液杂志, 2004, 9(4): 160-162.

［8］聂玲, 李璘, 杨艺红, 张战强, 于明华, 徐泽锋, 等. 骨髓增生异常综合征患者铁代谢状况及其对预后的影响［J］. 中华血液学杂志, 2009, 30(1): 50-53.

［9］Sasaki H, Manabe A, Kojima S, Tsuchida M, Hayashi Y, Ikuta K, et al. Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan［J］. Leukemia, 2001, 15(11): 1713-1720.

［10］何海龙, 柴忆欢, 何军, 朱玲琍. 儿童骨髓增生异常综合征细胞遗传学研究及临床意义［J］. 临床儿科杂志, 2006, 24(11): 896-898.

［11］蒋红飞, 杨明清. 骨髓增生异常综合征发病机制的研究进展［J］. 检验医学与临床杂志, 2004, 1(3): 123-126.

［12］张秋荣, 陈令松, 张桂华, 徐金格, 曹若男, 宋文炜. 骨髓增生异常综合征患者细胞及体液免疫功能分析［J］. 临床荟萃杂志, 2012, 27(1): 7-12.

［13］McKenna RW. Myelodysplasia and myeloproliferative disorders in children ［J］. Am J Clin Pathol, 2004, 122(Suppl): 58-69.

［14］Hasle H, Baumann I, Bergstr-sser E, Fenu S, Fischer A, Kardos G, et al. The international prognostic scoring system(IPSS) for childhood myelodysplastic syndrome(MDS) and juvenile myelomonocytic leukemia(JMML)［J］. Leukemia, 2004, 18(12): 2008-2014.

［15］肖志坚，郝玉书．儿童骨髓增生异常综合征的诊断分型［J］. 中华儿科杂志, 2005, 43(7): 545-547.

［16］Mandel K, Dror Y, Poon A, Freedman MH. A practical comprehensive classification for pediatric myelodysplastic syndromes: The CCC System［J］. J Pediatr Hematol Oncol, 2002, 24(7): 596-605.

［17］Mielot F, Buisine J, Duchayne E, Fenneteau O, Goasguen J, Guitard AM, et al. Myelodysplastic syndrome in childhood is the FAB classification relevant? Report of 81 children from a French multicentre study, French Group of Cellular Hematology［J］. Leuk Lymphoma, 1998, 28(5-6): 531-540.

［18］岳兰竹, 邵宗鸿. 骨髓增生异常综合征诊断研究进展－维也纳诊断标准及2008 WHO诊断标准解读［J］. 国际输血及血液学杂志，2010, 33(3): 195-198.

［19］吴南海, 栾佐, 杨平地, 徐世侠, 黄宁, 黄友章, 等. 国内首例同胞脐血移植治疗儿童骨髓增生异常综合征［J］. 中国当代儿科杂志, 2003, 5(6): 509-511.

［20］张茜, 白海, 王存邦, 葸瑞, 徐淑芬, 吴涛. 异基因造血干细胞移植治疗骨髓增生异常综合征9例［J］. 临床血液学杂志, 2009, 22(11): 617-618.